Efficacy of Hypomethylating Agents vs. Intensive Chemotherapy in Acute Myeloid Leukemia Using 5hmC as a Blood-Based Minimal Residual Disease Marker
The Methodist Hospital Research Institute
The Methodist Hospital Research Institute
University of Alabama at Birmingham
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Therapeutic Advances in Childhood Leukemia Consortium
M.D. Anderson Cancer Center
Novartis
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Princess Maxima Center for Pediatric Oncology
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Therapeutic Advances in Childhood Leukemia Consortium
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Masonic Cancer Center, University of Minnesota
Emory University
Hospital Israelita Albert Einstein
M.D. Anderson Cancer Center
Merck Sharp & Dohme LLC
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
Washington University School of Medicine
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
Eisai Inc.
National Cancer Institute (NCI)